|Grant Affiliation:||Weiss: Protection by Neutralizing Antibodies|
|Strategy:||Protein & peptide vaccines|
|Study Type:||Pre-Clinical Non-NHP|
|Study Start Date:||2011-02-10|
|Study Made Public:||2012-02-14|
Screening of gp41-HR1 based antigens for ability to elicit neutralizing antibodies
CAVD 342 is a preclinical guinea pig study investigating different prime-boost combinations of gp41-HR1 liposomes or peptide mimetics compared to control immunizations (R2 (Clade B), CN54 (Clade C) or SF162 (Clade B) gp140s.
Sign in to see full information about this study and to download study data.